OptiNose (OPTN) Commences Proposed Public Offering of Common Stock

Optinose (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced the commencement of a proposed underwritten public offering of shares of its common stock. All of the shares of common stock will be offered by Optinose. Optinose expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the total number of shares of common stock.

Optinose intends to use the net proceeds of the offering for working capital and general corporate purposes, including the commercialization of XHANCE, the clinical development of XHANCE for a follow‑on indication for the treatment of chronic sinusitis and the clinical development of OPN-019 for the treatment of COVID-19.

Credit Suisse Securities (USA) LLC will act as sole bookrunner for the proposed offering.

The securities will be offered and sold pursuant to Optinose’s effective registration statement on Form S-3 (File No. 333-228122) filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 1, 2018 and declared effective on November 9, 2018.

You May Also Be Interested In

• Definium Therapeutics prices $700M public offering at $34 per share
• Calidi Biotherapeutics adds biopharma veteran Corsee Sanders to board
• XTEND wins $9M Middle East drone contract, adds two patents